Preliminary results from a phase I/II study of 9MW2821, an antibody-drug conjugate targeting nectin-4, in patients with advanced solid tumors

被引：1
|
作者：
Zhang, J. [1 ]
Liu, R. [1 ]
Gao, S. [1 ]
Li, X. [2 ]
Chen, J. [3 ]
Yao, X. [4 ]
Fang, Y. [5 ]
Li, R. [6 ]
Zhang, M. [7 ]
Qiu, F. [8 ]
Li, Y. [9 ]
Liu, T. [10 ]
Huang, H. [11 ]
Zhang, X. [12 ]
Guo, H. [13 ]
Hu, B. [14 ]
Liu, J-Y. [15 ]
Yang, Q. [16 ]
Zhao, P. [17 ]
Wang, P. [18 ]
机构：
[1] Shanghai Canc Ctr, Phase I Clin Trial Ctr, Shanghai, Peoples R China
[2] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Peoples R China
[3] Yantai Yuhunagding Hosp, Dept Med Oncol, Yantai, Peoples R China
[4] Tianjin Canc Hosp, Dept Urol Oncol, Tianjin, Peoples R China
[5] Affiliated Canc Hosp Chongqing Univ, Dept Urol, Chongqing, Peoples R China
[6] Chongqing Univ Canc Hosp, Gynecol Oncol Ctr, Chongqing, Peoples R China
[7] Second Hosp Anhui Med Univ, Dept Med Oncol, Hefei, Peoples R China
[8] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Med Oncol, East Gate 1, Hangzhou, Peoples R China
[9] Shenyang Tenth Peoples Hosp, Dept Oncol, Shenyang, Peoples R China
[10] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China
[11] Wenzhou Med Univ, Affiliated Hosp 1, Dept Urinary Surg, Nanbaixiang Site, Wenzhou, Peoples R China
[12] Wuhan Union Hosp, Dept Urol, Wuhan, Peoples R China
[13] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Urol, Nanjing, Peoples R China
[14] Liaoning Canc Hosp & Inst, Dept Urol, Shenyang, Peoples R China
[15] Sichuan Univ, West China Hosp, West China Sch Med, Dept Biotherapy, Chengdu, Peoples R China
[16] Sun Yat Sen Univ, Affiliated Hosp 2, Phase I Clin Trial Ctr, Guangzhou, Peoples R China
[17] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Peoples R China
[18] Mabwell Shanghai Biosci Co Ltd, Clin Med Dept, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1845
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
659MO
引用
收藏
页码：S464 / S464
页数：1
相关论文
共 50 条
  • [1] 9MW2821, a nectin-4 antibody-drug conjugate (ADC), in patients with advanced solid tumor: Results from a phase 1/2a study.
    Zhang, Jian
    Liu, Rujiao
    Gao, Shuiping
    Yang, Huijuan
    Chen, Jian
    Yuan, Fang
    Liu, Jiyan
    Guo, Hongqian
    Zhang, Shun
    Li, XingYa
    Yao, Xin
    Bai, Ming
    Bu, Hualei
    Li, Yinyin
    Hu, Changlu
    Li, Xiumin
    Wang, Zhen
    Wang, ShanBing
    Lou, Hanmei
    Feng, Zhe
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Development and validation of bioanalytical assays for the quantification of 9MW2821, a nectin-4-targeting antibody-drug conjugate
    Fang, Peng
    You, Meng
    Cao, Yuxia
    Feng, Qingjun
    Shi, Lei
    Wang, Jin
    Sun, Xiaowei
    Yu, Dongan
    Zhou, Wei
    Yin, Long
    Mei, Fei
    Zhu, Xiaohong
    Cheng, Aidi
    Tan, Xiaoding
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2024, 248
  • [3] Efficacy and safety of 9 MW2821, an antibody-drug conjugate targeting Nectin-4 monotherapy, in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, phase I/II study
    Yang, Huijuan
    Zhang, Jian
    Liu, Rujiao
    Gao, Shuiping
    Lou, Hanmei
    Li, Guiling
    Bu, Hualei
    Li, Rong
    Wang, Shanbing
    Shen, Shujing
    Zhang, Mingjun
    Wang, Peipei
    Feng, Zhe
    Chu, Nan
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S22 - S23
  • [4] Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers
    Zhou, Wei
    Fang, Peng
    Yu, Dongan
    Ren, Hongyuan
    You, Meng
    Yin, Long
    Mei, Fei
    Zhu, Huikai
    Wang, Zhenzhen
    Xu, Hui
    Cao, Yuxia
    Sun, Xiaowei
    Xu, Xiaohong
    Bi, Jianjun
    Wang, Jin
    Ma, Lanping
    Wang, Xin
    Chen, Lin
    Zhang, Yongliang
    Cen, Xiaowei
    Zhu, Xi
    Lou, Liguang
    Liu, Datao
    Tan, Xiaoding
    Yang, Jinliang
    Meng, Tao
    Shen, Jingkang
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (08) : 913 - 925
  • [5] A phase 1 study of LY4101174 (ETx-22), an antibody-drug conjugate targeting nectin-4, in patients with advanced or metastatic urothelial cancer and other solid tumors (trial in progress)
    Rosenberg, Jonathan
    Sabatier, Renaud
    Viceneux, Armelle
    Rouge, Thibault De la Motte
    Champiat, Stephane
    Lebellec, Loic
    Barthelemy, Philippe
    Sonpavde, Guru
    Gao, Xin
    Niglio, Scot
    Zhang, Tian
    Gedye, Craig
    Galsky, Matthew
    Milowsky, Matthew
    Reimers, Melissa
    Weickhardt, Andrew
    Grande, Enrique
    Castellano, Daniel E.
    Bilen, Mehmet
    Patnaik, Amita
    Zerbib, Robert
    Balbas, Minna
    Xu, Xiaojian
    Aptaker, Kaitlyn
    Balar, Arjun V.
    Awada, Ahmad H.
    CANCER RESEARCH, 2024, 84 (07)
  • [6] NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors (Trial in Progress)
    Baldini, C.
    Patnaik, A.
    Lakhani, N.
    Call, J.
    Galsky, M.
    Garmezy, B.
    Wei, A.
    Carter, L.
    Powles, T.
    Siefker-Radtke, A.
    O'Donnell, P. H.
    Kitano, S.
    Castellano, D. E.
    Shinde, R.
    Joshua, A. M.
    Balbas, M.
    Han, H.
    Chang, A. E.
    Gao, X.
    Iyer, G.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S66 - S66
  • [7] Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma
    Ott, Patrick A.
    Hamid, Omid
    Pavlick, Anna C.
    Kluger, Harriet
    Kim, Kevin B.
    Boasberg, Peter D.
    Simantov, Ronit
    Crowley, Elizabeth
    Green, Jennifer A.
    Hawthorne, Thomas
    Davis, Thomas A.
    Sznol, Mario
    Hwu, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (32) : 3659 - +
  • [8] A phase 1 study of PF-06647020, an antibody-drug conjugate targeting PTK7, in patients with advanced solid tumors
    Tolcher, A. W.
    Calvo, E.
    Maitland, M. L.
    Gibson, B.
    Xuan, D.
    Joh, T.
    Jackson-Fischer, A.
    Damelin, M.
    Barton, J.
    Xin, X.
    Sachdev, J. C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S724 - S724
  • [9] Preliminary results from a phase 1 study of the antibody-drug conjugate ABBV-221 in patients with solid tumors likely to express EGFR.
    Calvo, Emiliano
    Cleary, James M.
    Moreno, Victor
    Gifford, Maryella
    Roberts-Rapp, Lisa
    Ansel, Peter J.
    Mittapalli, Rajendar K.
    Lee, Ho-jin
    Hu, Beibei
    Barch, David
    Ocampo, Christopher Joseph
    Tolcher, Anthony W.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Phase I/II Study of CR011-vcMMAE, an Antibody-drug Conjugate Targeting GPNMB, for the Treatment of Patients With Advanced Melanoma
    Hwu, Patrick
    Sznol, M.
    Pavlick, A.
    Kluger, H.
    Kim, K. B.
    Hwu, W. J.
    Papadopoulos, N.
    Sanders, D.
    Boasberg, P.
    Simantov, R.
    Hamid, O.
    JOURNAL OF IMMUNOTHERAPY, 2008, 31 (09) : 970 - 971
12345